[1]李 焰,何 山,郑 轲,等.化疗后续用三苯氧胺对乳腺癌患者激素水平的影响[J].医学信息,2019,(20):133-135.[doi:10.3969/j.issn.1006-1959.2019.20.041]
 LI Yan,HE Shan,ZHENG Ke,et al.Effect of Chemotherapy Followed by Tamoxifen on Hormone Levels in Patients with Breast Cancer[J].Medical Information,2019,(20):133-135.[doi:10.3969/j.issn.1006-1959.2019.20.041]
点击复制

化疗后续用三苯氧胺对乳腺癌患者激素水平的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年20期
页码:
133-135
栏目:
药物与临床
出版日期:
2019-10-15

文章信息/Info

Title:
Effect of Chemotherapy Followed by Tamoxifen on Hormone Levels in Patients with Breast Cancer
文章编号:
1006-1959(2019)20-0133-03
作者:
李 焰何 山郑 轲张艳珍李燕茹
(四川省宜宾市第二人民医院乳腺甲状腺外科,四川 宜宾 644000)
Author(s):
LI YanHE ShanZHENG KeZHANG Yan-zhenLI Yan-ru
(Department of Breast and Thyroid Surgery,the Second People's Hospital of Yibin City,Yibin 644000,Sichuan,China)
关键词:
乳腺癌三苯氧胺雌二醇黄体生成素卵泡刺激素
Keywords:
reast cancerTamoxifenEstradiolLuteinizing hormoneFollicle stimulating hormone
分类号:
R445.1
DOI:
10.3969/j.issn.1006-1959.2019.20.041
文献标志码:
A
摘要:
目的 探讨乳腺癌患者化疗后续用三苯氧胺对激素水平的影响。方法 选取2015年1月~2018年12月我院收治的乳腺癌患者82例,采用随机数字表法分为继用三苯氧胺组(n=40)及停用三苯氧胺组(n=42),比较两组不同时间点(T0、T1、T2、T3、T4)E2、LH、FSH水平变化情况。结果 两组E2水平均较治疗前升高,差异具有统计学意义(P<0.05);FSH、LH水平较治疗前升高,但差异无统计学差异(P>0.05)。继用三苯氧胺组不同时间点E2、FSH、LH水平比较,差异无统计学意义(P>0.05);停用三苯氧胺组T3、T4时间点E2水平较T1、T2 时间点低,差异有统计学意义(P<0.05),不同时间点FSH、LH水平比较,差异无统计学差异(P>0.05)。结论 化疗后续用三苯氧胺可影响乳腺癌患者E2水平,对于FSH及LH水平无明显影响,服用三苯氧胺期间对卵巢功能的判断应停药后多次测量。
Abstract:
Objective To investigate the effect of tamoxifen on hormone levels in patients with breast cancer after chemotherapy.Methods A total of 82 patients with breast cancer admitted to our hospital from January 2015 to December 2018 were enrolled. The randomized digital table method was divided into the tamoxifen group (n=40) and the tamoxifen group (n=42). The changes of E2, LH and FSH levels at different time points (T0,T1,T2,T3,T4) were compared between the two groups.Results The E2 levels in the two groups were higher than those before treatment, the difference was statistically significant (P<0.05). The levels of FSH and LH were higher than those before treatment, but the difference was not statistically significant (P>0.05). There were no significant differences in the levels of E2, FSH and LH between the tamoxifen groups at different time points (P>0.05). The levels of E2 at T3 and T4 in the tamoxifen group were lower than those at T1 and T2, the difference was statistically significant(P<0.05), there was no significant difference in FSH and LH levels at different time points (P>0.05).Conclusion The subsequent use of tamoxifen in chemotherapy can affect the E2 level of breast cancer patients. There is no significant effect on the levels of FSH and LH. The judgment of ovarian function during tamoxifen should be measured after repeated withdrawal.

参考文献/References:

[1]Yu Z,Guo X,Jiang Y,et al.Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive:a systemic review and network meta-analysis[J].Breast Cancer,2017,25(1):8-16. [2]李焰,蒲玉平,郑轲,等.化疗对乳腺癌患者激素水平及月经状态的影响[J].现代生物医学进展,2018,18(12):157-160,174. [3]黄兵江,樊涛,郑静,等.绝经前乳腺癌治疗手段与闭经相关性的研究进展[J].实用医学杂志,2018,34(2):331-334. [4]Gradishar WJ,Anderson BO,Balassanian R,et al.Invasive Breast Cancer Version1.2016,NCCN Clinical Practice Guidelines in Oncology[J].Journal of the National Comprehensive Cancer Network,2016,14(3):324. [5]中国抗癌协会乳腺癌专业委员会.中国绝经前女性乳腺癌患者辅助治疗后绝经判断标准及芳香化酶抑制剂临床应用共识[J].中国癌症杂志,2012,22(3):321-323. [6]中国抗癌协会乳腺癌专业委员会.中国早期乳腺癌卵巢功能抑制临床应用专家共识(2018年版)[J].中国癌症杂志,2018,28(11):76-85. [7]中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2015版)[J].中国癌症杂志,2015,25(9):692-753. [8]杨慧芬,罗华,杨欧欧,等.绝经前Luminal型乳腺癌患者血清生殖激素水平与内分泌治疗后血管舒缩功能障碍的相关性研究[J].浙江创伤外科,2016(1):1-4. [9]王华龙,王鸿波,单世胜,等.阿那曲唑和他莫昔芬对绝经后乳腺癌患者子宫内膜、血脂代谢、免疫功能和性激素的影响[J].解放军医药杂志,2018,30(5):40-43. [10]杨新明,吴绍洋,陈莉丽,等.三苯氧胺对乳腺癌围绝经期患者性激素水平的影响[J].中国医药导报,2011,8(30):74-75. [11]Madeddu C,Gramignano G,Kotsonis P,et al.Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer:A report of two cases[J].Oncology Letters,2014,8(3):1279-1282. [12]闫莉.方玄驹胶囊联合他莫昔芬对多囊卵巢综合征不孕患者性激素水平变化及妊娠率的影响[J].中国民间疗法,2019,27(4):71-73. [13]王健,赵冬梅,范宇.乳腺癌患者长期口服三苯氧胺对激素水平影响[J].中国实用医药,2013,8(31):239-240.

相似文献/References:

[1]董 云.SPECT/CT 双时相99mTc- MIBI断层显像 在乳腺癌诊断中的应用[J].医学信息,2018,(05):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
 DONG Yun.Application of SPECT/CT Dual-phase 99mTc-MIBI Tomography in the Diagnosis of Breast Cancer[J].Medical Information,2018,(20):147.[doi:10.3969/j.issn.1006-1959.2018.05.053]
[2]于 东.平消片为主组合方案治疗乳腺增生症临床分析[J].医学信息,2018,(08):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
 YU Dong.Clinical Analysis of the Combination of Pingxiao Tablets in the Treatment of Mammary Hyperplasia[J].Medical Information,2018,(20):136.[doi:10.3969/j.issn.1006-1959.2018.08.046]
[3]李建辉,祝旭龙.乳腺癌的治疗管理——把好生活质量关[J].医学信息,2018,(13):1.[doi:10.3969/j.issn.1006-1959.2018.13.001]
[4]杨玉峰,李 强,曲国红,等.乳腺癌术前巴德枪穿刺检测ER、PR的临床研究[J].医学信息,2018,(13):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
 YANG Yu-feng,LI Qiang,QU Guo-hong,et al.Clinical Study on Preoperative ER and PR Detection of Bard Gun Puncture in Breast Cancer[J].Medical Information,2018,(20):163.[doi:10.3969/j.issn.1006-1959.2018.13.050]
[5]刘 曼,厉玛倩倩,徐润润,等.延续性护理对乳腺癌术后化疗患者生活质量与 健康知识水平的影响[J].医学信息,2018,(16):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
 LIU Man,LIMA Qian-qian,XU Run-run,et al.Effect of Continuous Nursing on Quality of Life and Health Knowledge of Postoperative Chemotherapy Patients with Breast Cancer[J].Medical Information,2018,(20):178.[doi:10.3969/j.issn.1006-1959.2018.16.057]
[6]张艳萍,曹 玉,孙国平.服用阿司匹林对乳腺癌患者生存获益的Meta分析[J].医学信息,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
 ZHANG Yan-ping,CAO Yu,SUN Guo-ping.Meta Analysis of the Survival Benefit of Patients with Breast Cancer Treated with Aspirin[J].Medical Information,2018,(20):72.[doi:10.3969/j.issn.1006-1959.2018.20.021]
[7]钟 磊,谢海燕,林 霖.电化学发光免疫分析技术检测肿瘤标志物在乳腺癌诊断中的应用[J].医学信息,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
 ZHONG Lei,XIE Hai-yan,LIN Lin.Application of Electrochemiluminescence Immunoassay for Detection of Tumor Markers in Diagnosis of Breast Cancer[J].Medical Information,2018,(20):155.[doi:10.3969/j.issn.1006-1959.2018.20.048]
[8]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
 HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,(20):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[9]阙海涛,曹 斌,秦志刚.EGFL7在乳腺癌中的研究进展[J].医学信息,2018,(23):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
 QUE Hai-tao,CAO Bin,QIN Zhi-gang.Research Progress of EGFL7 in Breast Cancer[J].Medical Information,2018,(20):32.[doi:10.3969/j.issn.1006-1959.2018.23.010]
[10]张文婧,宋 冰.HER-2阳性乳腺癌分子靶向治疗进展[J].医学信息,2018,(24):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]
 ZHANG Wen-jing,SONG Bing.Progress in Molecular Targeted Therapy for HER-2 Positive Breast Cancer[J].Medical Information,2018,(20):42.[doi:10.3969/j.issn.1006-1959.2018.24.012]

更新日期/Last Update: 2019-10-15